Vancomycin and the D-Ala-D-Lac Escape: The VRE Resistance Switch

What VRE Is and Why It Matters at the Bedside

Enterococci — chiefly Enterococcus faecium and E. faecalis — are hardy Gram-positive gut commensals that turn opportunistic in hospitalized, immunocompromised, or instrumented patients. They cause urinary tract infections, intra-abdominal and pelvic infections, catheter-associated bloodstream infections, and endocarditis. Vancomycin-resistant enterococci (VRE) are strains that have lost susceptibility to vancomycin, historically a mainstay against Gram-positive organisms.

• Clinical weight: VRE bloodstream infection carries higher mortality and longer stays than vancomycin-susceptible enterococci, partly from delayed effective therapy.
• Epidemiology: E. faecium accounts for the majority of clinical VRE; the CDC classifies VRE as a serious threat, with tens of thousands of hospital infections annually in the US.
• Transmission: VRE persists on surfaces and hands, spreading via the fecal-oral route in healthcare settings.

Crucially, the vanA/vanB resistance cassettes are carried on mobile genetic elements, raising the feared possibility of transfer to Staphylococcus aureus — a scenario documented in rare vancomycin-resistant S. aureus (VRSA) isolates.

The Mechanism, Step by Step: Rebuilding the Target

Vancomycin does not attack an enzyme — it is a bulky glycopeptide that binds the D-Ala-D-Ala terminus of the lipid II peptidoglycan precursor through five hydrogen bonds, sterically blocking transglycosylation and transpeptidation. Starve the wall of cross-links and the bacterium lyses.

VRE defeats this by manufacturing a decoy terminus. The inducible vanHAX operon does the work:

• VanH — a dehydrogenase that reduces pyruvate to D-lactate, supplying raw material.
• VanA (or VanB) — a ligase that joins D-Ala to D-Lac, producing the depsipeptide D-Ala-D-Lac instead of the normal dipeptide.
• VanX — a D,D-dipeptidase that destroys any residual native D-Ala-D-Ala, ensuring the drug has nothing to grab.

Replacing the terminal amide (–NH–) with an ester (–O–) deletes one hydrogen-bond donor and introduces electrostatic repulsion, dropping vancomycin affinity roughly 1,000-fold. The whole system is switched on by the VanS/VanR two-component signal system: membrane sensor kinase VanS detects glycopeptide-induced cell-wall stress and phosphorylates the response regulator VanR, which transcribes the operon only when the drug is present.

Clinical Presentation: There Is No 'VRE Syndrome'

A key teaching point: VRE has no distinctive clinical picture of its own. The resistance switch changes what will treat the infection, not how it presents. Patients show the syndrome of whatever site is infected:

• Bacteremia / catheter-associated bloodstream infection: fever, rigors, hemodynamic instability — often in a patient with a central line, neutropenia, or recent broad-spectrum antibiotics.
• Urinary tract infection: commonly catheter-associated; may be asymptomatic bacteriuria versus true cystitis/pyelonephritis — a frequent overtreatment trap.
• Intra-abdominal / pelvic infection: as part of polymicrobial abscesses and post-surgical infections.
• Endocarditis: subacute course; enterococci are the third-leading cause of infective endocarditis.

The real "presentation" clinicians recognize is epidemiologic risk: prolonged hospitalization, ICU stay, prior vancomycin or cephalosporin exposure, hemodialysis, transplant, hematologic malignancy, and known VRE colonization. Colonization vastly outnumbers infection — most patients who "grow VRE" on a surveillance swab are colonized, not infected, and treating colonization is a mistake.

Diagnosis: MIC Breakpoints, Genotyping, and the Teicoplanin Clue

Diagnosis is microbiologic, not clinical. The organism is identified from a normally sterile site (blood, deep tissue) and tested for susceptibility.

• MIC breakpoints (CLSI): vancomycin MIC ≤4 µg/mL = susceptible, 8–16 µg/mL = intermediate, ≥32 µg/mL = resistant. VanA strains often reach 64–1024 µg/mL.
• Phenotypic clue: testing teicoplanin separates the two big genotypes — VanA is teicoplanin-resistant (VanS senses teicoplanin too), whereas VanB is teicoplanin-susceptible because teicoplanin does not induce the vanB operon.
• Genotypic confirmation: PCR for vanA/vanB genes; rapid molecular assays and chromogenic screening agars support infection-control surveillance.

A diagnostic pitfall worth naming: low-MIC vanB strains (some as low as 4 µg/mL, at or below the susceptible breakpoint) can be missed by automated systems, which is why PCR and specialized screening are used in outbreak settings. Automated instruments detect vanA far more reliably than low-level vanB.

Management at a Mechanism Level: Why Each Drug Still Works

Because vancomycin's target is gone, therapy pivots to agents that hit different targets:

• Linezolid (oxazolidinone) — binds the 23S rRNA of the 50S ribosomal subunit, blocking initiation-complex formation. Bacteriostatic; oral option; watch for thrombocytopenia, serotonin syndrome (MAOI activity), and neuropathy with prolonged use. First-line for many VRE infections including E. faecium.
• Daptomycin — a lipopeptide that inserts into the membrane in a calcium-dependent way, causing depolarization and rapid killing. Bactericidal; preferred by many for VRE bacteremia/endocarditis, often at high doses; monitor creatine kinase (myopathy) and note it is inactivated by pulmonary surfactant (never for pneumonia).
• Ampicillin — still first-line for susceptible E. faecalis, which is usually ampicillin-sensitive; E. faecium is typically ampicillin-resistant.
• Others: tigecycline, quinupristin-dalfopristin (E. faecium only), and newer oxazolidinones for salvage.

Two mechanism-level pitfalls: emergent daptomycin resistance during therapy (membrane remodeling) and linezolid-resistance from ribosomal or cfr/optrA mutations. Source control — removing infected lines and draining abscesses — remains as important as the drug.

Mimics, Distinctions, and Do-Not-Miss Pitfalls

Not all vancomycin resistance is the same switch, and distinguishing them changes management and infection control:

• Intrinsic vs acquired: E. gallinarum and E. casseliflavus carry chromosomal vanC, producing D-Ala-D-Ser and only low-level, non-transferable resistance — a lab curiosity that should not trigger the same contact-precaution alarm as vanA/vanB.
• Colonization vs infection: the single biggest error is treating a positive VRE swab or asymptomatic bacteriuria. Antibiotics for colonization drive further resistance without benefit.
• The VRSA nightmare: the same vanA operon (on Tn1546) can jump to S. aureus, producing genuinely vancomycin-resistant S. aureus — distinct from the far commoner VISA (thickened cell wall, decoy targets) and hVISA subpopulations.
• Don't confuse the phenotype label: "VanA" refers to the resistance operon/phenotype, not to a single enzyme in isolation — VanA the ligase is one gene within the vanHAX cluster.

The unifying insight: this is target modification, the antibiotic-resistance strategy of remodeling the drug's binding site rather than pumping the drug out or chewing it up — the same logic as PBP2a in MRSA.

Major VRE resistance phenotypes and how they differ clinically

Feature	VanA	VanB	VanC (E. gallinarum/casseliflavus)
Ligase product	D-Ala-D-Lac (depsipeptide)	D-Ala-D-Lac (depsipeptide)	D-Ala-D-Ser
Vancomycin MIC	High (≥64–1024 µg/mL)	Variable (4–1024 µg/mL)	Low-level (8–32 µg/mL)
Teicoplanin	Resistant	Susceptible	Susceptible
Genetic element	Tn1546 transposon, mobile/plasmid	Tn1547/Tn5382, mobile	Chromosomal, intrinsic
Transferable	Yes (high risk)	Yes	No (species-intrinsic)
Typical species	E. faecium > E. faecalis	E. faecium, E. faecalis	E. gallinarum, E. casseliflavus